ReviewSe pu = Chinese journal of chromatography2026
[Design and synthesis of molecularly imprinted polymers and their applications in medical diagnosis and biocatalysis].
Review in Se pu = Chinese journal of chromatography, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Molecularly imprinted technology (MIT) represents an advanced synthetic strategy that emulates biological recognition mechanisms, such as antigen-antibody or enzyme-substrate interactions, by creating three-dimensional cavity-like structures through the directional assembly of functional monomers around a template molecule. This process generates spatial and functional complementarity, enabling highly selective recognition of target species. Molecularly imprinted polymers (MIPs), often described as "synthetic antibodies", overcome the intrinsic limitations of natural biomolecules by offering superior selectivity, robustness, cost-effectiveness, and structural tunability. These features position MIPs as promising alternatives to natural antibodies in targeted sensing and drug delivery, with broad applications across biomedical, environmental, and pharmaceutical domains, including pollutant detection, and food safety monitoring. Despite substantial progress, key challenges remain, such as uneven imprinting layers, template residue, and limited aqueous compatibility in macromolecular imprinting. Furthermore, issues of industrial scalability, unclear recognition mechanisms, and insufficient integration with emerging fields such as microfluidics and artificial intelligence have hindered large-scale translation. In recent years, our research team has systematically advanced MIT through a tri-dimensional strategy encompassing high-throughput monomer screening, mechanistic elucidation of molecular recognition, and directional assembly of functional units. By establishing a standardized monomer library and integrating molecular dynamics simulations, we achieved precise material design under complex conditions. Through process optimization and material innovation, we developed a highly efficient solid-phase surface imprinting method that enables the fabrication of smart MIPs with stimuli-responsive properties (e.g., temperature and pH). These MIPs exhibit markedly enhanced binding affinity, with equilibrium dissociation constant (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.